Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

Tamoxifen resistance is accountable for relapse in many ER-positive breast cancer patients. Most of these recurrent patients receive chemotherapy, but their chemosensitivity is unknown. Here, we report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nat Commun
Auteurs principaux: Zhu, Yinghua, Liu, Yujie, Zhang, Chao, Chu, Junjun, Wu, Yanqing, Li, Yudong, Liu, Jieqiong, Li, Qian, Li, Shunying, Shi, Qianfeng, Jin, Liang, Zhao, Jianli, Yin, Dong, Efroni, Sol, Su, Fengxi, Yao, Herui, Song, Erwei, Liu, Qiang
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5913295/
https://ncbi.nlm.nih.gov/pubmed/29686231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03951-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires